Bausch + Lomb Corporation (NYSE:BLCO) Receives $15.60 Average PT from Brokerages

Shares of Bausch + Lomb Corporation (NYSE:BLCO) have been assigned an average rating of “Hold” from the thirteen brokerages that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $15.70.

BLCO has been the subject of a number of analyst reports. Evercore ISI upped their price target on Bausch + Lomb from $16.50 to $17.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bausch + Lomb in a report on Wednesday. Wells Fargo & Company upped their price target on Bausch + Lomb from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. Zacks Research raised Bausch + Lomb to a “hold” rating in a report on Tuesday, August 12th. Finally, Citigroup reissued a “neutral” rating on shares of Bausch + Lomb in a report on Tuesday.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds have recently made changes to their positions in the company. Deutsche Bank AG acquired a new position in shares of Bausch + Lomb during the first quarter valued at approximately $50,750,000. Alberta Investment Management Corp increased its holdings in shares of Bausch + Lomb by 8.6% in the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company’s stock valued at $47,360,000 after purchasing an additional 258,000 shares during the last quarter. Goldentree Asset Management LP increased its holdings in shares of Bausch + Lomb by 14.9% in the second quarter. Goldentree Asset Management LP now owns 2,583,185 shares of the company’s stock valued at $33,524,000 after purchasing an additional 334,916 shares during the last quarter. Oaktree Capital Management LP acquired a new stake in shares of Bausch + Lomb in the second quarter valued at approximately $32,801,000. Finally, Glenview Capital Management LLC increased its holdings in shares of Bausch + Lomb by 210.8% in the second quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock valued at $20,216,000 after purchasing an additional 1,053,855 shares during the last quarter. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Stock Down 0.5%

Shares of BLCO opened at $14.35 on Tuesday. Bausch + Lomb has a 52 week low of $10.45 and a 52 week high of $21.69. The company has a quick ratio of 0.98, a current ratio of 1.55 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $5.08 billion, a price-to-earnings ratio of -18.40, a PEG ratio of 1.57 and a beta of 0.63. The stock’s 50-day moving average price is $14.68 and its 200-day moving average price is $13.31.

Bausch + Lomb (NYSE:BLCO) last issued its earnings results on Wednesday, July 30th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Bausch + Lomb had a positive return on equity of 2.33% and a negative net margin of 5.58%.The firm had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the prior year, the business earned $0.13 earnings per share. The company’s revenue was up 5.1% compared to the same quarter last year. Bausch + Lomb has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Bausch + Lomb will post 0.74 EPS for the current year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.